Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Inflectra Reviewers

Executive Summary

FDA staff who participated in the agency's review of Celltrion's infliximab-dyyb, a biosimilar to Janssen's Remicade.

Advertisement

Related Content

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans
Inflectra Clinical Development Timeline

Topics

Advertisement
UsernamePublicRestriction

Register